Background/Aims Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics of 48-week treatment with linvencorvir plus standard of care (SoC) in CHB patients.
Methods This was a multicentre, non-randomized, non-controlled, open-label phase 2 study enrolling three cohorts: nucleos(t)ide analogue (NUC)-suppressed patients received linvencorvir plus NUC (Cohort A, n=32); treatment-naïve patients received linvencorvir plus NUC without (Cohort B, n=10) or with (Cohort C, n=30) pegylated interferon-α (Peg-IFN-α). Treatment duration was 48 weeks, followed by NUC alone for 24 weeks.
Results 68 patients completed the study. No patient achieved functional cure (sustained HBsAg loss and unquantifiable HBV DNA). By Week 48, 89% of treatment-naïve patients (10/10 Cohort B; 24/28 Cohort C) reached unquantifiable HBV DNA. Unquantifiable HBV RNA was achieved in 92% of patients with quantifiable baseline HBV RNA (14/15 Cohort A, 8/8 Cohort B, 22/25 Cohort C) at Week 48 along with partially sustained HBV RNA responses in treatment-naïve patients during follow-up period. Pronounced reductions in HBeAg and HBcrAg were observed in treatment-naïve patients, while HBsAg decline was only observed in Cohort C. Most adverse events were grade 1–2, and no linvencorvir-related serious adverse events were reported.
Conclusions 48-week linvencorvir plus SoC was generally safe and well tolerated, and resulted in potent HBV DNA and RNA suppression. However, 48-week linvencorvir plus NUC with or without Peg-IFN did not result in the achievement of functional cure in any patient.
Citations
Citations to this article as recorded by
Current status and challenges of therapeutic targets, novel drugs and delivery systems for hepatitis B: how far to our goal? Yanmei Liao, Fei Lv, Mei Zhou, Jie Shen, Tianwen Quan Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease Chunting Zhu, Jie Yang, Yu Sheng, Min Fang Frontiers in Immunology.2026;[Epub] CrossRef
Hepatitis B virus infection and its treatment in Eastern Ethiopia Tatsuo Kanda, Reina Sasaki-Tanaka, Atsunori Tsuchiya, Shuji Terai World Journal of Hepatology.2025;[Epub] CrossRef
Functional Cure for Hepatitis B Virus: Challenges and Achievements Oren Shechter, Daniel G. Sausen, Harel Dahari, Andrew Vaillant, Scott J. Cotler, Ronen Borenstein International Journal of Molecular Sciences.2025; 26(8): 3633. CrossRef
Advances in the computational development of hepatitis B virus capsid assembly modulators Ke Liu, Shaoqing Du, Weiqiao Deng, Zongjin Qu, Xueping Hu Drug Discovery Today.2025; 30(10): 104458. CrossRef
HBc: the multifunctional architect of HBV replication, immune evasion, and therapeutic innovation Yujia Zhu, Hongxiao Song, Fengchao Xu, Mian Huang, Guangyun Tan Frontiers in Immunology.2025;[Epub] CrossRef
Multisite Occupancy and Multidimensional Optimization: Design and Evaluation of Piperazine-Thioureidobenzamide Derivatives as Potent HBV Capsid Assembly Modulators Minghui Liang, Yutong Dou, Jian Zhang, Zechun Yang, Yuanyuan Liu, Mei Wang, Yiyan Mao, Lindan Guan, Aixin Li, Yuqing Cai, Yan Wang, Peng Xue, Lei Zhang, Zhuanchang Wu, Xinyong Liu, Peng Zhan, Haiyong Jia Journal of Medicinal Chemistry.2025; 68(22): 24358. CrossRef
Linvencovir: Paving the way for functional cure in hepatitis B Jiwon Yang, Jonggi Choi Clinical and Molecular Hepatology.2024; 30(2): 164. CrossRef
Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim Clinical and Molecular Hepatology.2024; 30(3): 539. CrossRef
Novel mechanistic insights – A brand new Era for anti-HBV drugs Weiping Lyu, Haoming Qin, Qi Li, Dehua Lu, Cheng Shi, Kangchen Zhao, Shengran Zhang, Ruohan Yu, Huiying Zhang, Xiaonan Zhou, Sitian Xia, Liangren Zhang, Xiaoqian Wang, Xiaowei Chi, Zhenming Liu European Journal of Medicinal Chemistry.2024; 279: 116854. CrossRef
Accuracy and readability of LLM-generated responses for gout management: a benchmark study based on ACR guidelines Zhuhai Shao, Yiwen Zhang, Bingfei Cheng, Fang Zhang, Xuhua Zhu, Zhongchao Wang, Yangang Wang, Lili Xu, Zepeng Mu Clinical Rheumatology.2026;[Epub] CrossRef
Revolutionizing MASLD: How Artificial Intelligence Is Shaping the Future of Liver Care Nicola Pugliese, Arianna Bertazzoni, Cesare Hassan, Jörn M. Schattenberg, Alessio Aghemo Cancers.2025; 17(5): 722. CrossRef
Large language models in thyroid diseases: Opportunities and challenges Yiwen Zhang, Pengfei Li, Lili Xu, Xuejuan Zhang, Hongwei Ji, Yangang Wang EngMedicine.2025; 2(2): 100076. CrossRef
Preliminary fatty liver disease grading using general-purpose online large language models: ChatGPT-4 or Bard? Yiwen Zhang, Hanyun Liu, Bin Sheng, Yih Chung Tham, Hongwei Ji Journal of Hepatology.2024; 80(6): e279. CrossRef
The performance of large language model-powered chatbots compared to oncology physicians on colorectal cancer queries Shan Zhou, Xiao Luo, Chan Chen, Hong Jiang, Chun Yang, Guanghui Ran, Juan Yu, Chengliang Yin International Journal of Surgery.2024; 110(10): 6509. CrossRef
First
Prev
